Abstract 254P
Background
Cervical cancer is the fourth most common cancer among women worldwide. In India, cervical cancer ranks second among women and there are estimated 96922 newly diagnosed cervical cancer cases and 60078 deaths. Most women present late to medical care facility due to lack of awareness. The management depends on the stage of the tumour, and includes surgery, chemotherapy and radiation. Prognosis of cervical cancer has improved recently due to novel treatment and screening approaches. Improving the quality of life is one of the most important parameters in the management of cervical cancer. Sexual function which is the principal dimension, is frequently compromised by late effects of the disease, and late treatment toxicities. This single center prospective study is one of the few studies which determine how cervical cancer and its treatment can affect the sexuality.
Methods
In this prospective study, conducted from April 2021 to April 2022, in Rajiv Gandhi Government general Hospital, Chennai, India. Post treatment 98 cervical cancer patients, 98 patients of non-gynaecological cancer and a group of 98 healthy women were recruited. Clinical features and Female Sexual Function Index (consists of desire, arousal, lubrication, orgasm, satisfaction, pain) of 3 balanced groups of women were compared.
Results
Higher rates of lymphedema were reported in cervical cancer group. About 99% of patients reported stopping their sexual activity completely during treatment; time to regular sexual activity was 9 months for the cervical cancer group, and 5 months for non-gynaecologic cancer (P =0.001). Mean vaginal length which was assessed by pelvic examination were 5.8 cm, 9.7 cm and 9.8 cm respectively for the cervical cancer group, non-gynaecologic cancer group and the control group (p=0.04). 6 parameter FSFI questionnaire, revealed worse results in the cervical cancer group (mean score was 18.3), but was statistically insignificant.
Conclusions
Sexual function, an important element for an optimal quality of life should be duly addressed throughout treatment, especially radiation. However statistically insignificant, poor sexual function indices in cervical cancer group in our study necessitates psychological component to be included in the multidisciplinary management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03